ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1471

ECV304 Cells Self-Citrullinate Proteins Targeted By Anti-Citrullinated Protein/Peptide Autoantibodies from Rheumatoid Arthritis Patients

Natalia Regine de Franca Shimabukuro1,2, Maximilien Lora1, Mariana Useche3, Zhijie Zhou4, Joyce Rauch5, Luis Eduardo Coelho Andrade2, Henri Menard1 and Ines Colmegna6, 1The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2Federal University of São Paulo, São Paulo, Brazil, 3Medicine, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 4Aurora Medical Centre, Oshkosh, WI, 5Division of Rheumatology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 6The Research Institute of the McGill University Health Centre, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies, autoantibodies, citrullination and rheumatoid arthritis (RA), PAD

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-citrullinated protein/peptide autoantibodies (ACPAs) define a major subset of rheumatoid arthritis (RA) patients. Cyclic citrullinated peptides (CCP) are commonly used as the antigen for assessing ACPAs. However, these synthetic peptides may not represent the citrullinated proteins found in vivo. We have utilized ECV304, a human cell line containing high protein arginine deiminases (PAD) levels, to generate a naturally derived citrullinome. Next, we assessed by proteomics the ECV304 antigens recognized by antibodies present in RA sera. Finally, we compared the performance of an in house ECV304-based ELISA with that of a commercial anti-CCP2-ELISA for RA diagnosis.

Methods: Citrullination was assessed in ECV 304 and other human cell lines (n=7) by Western blot and the amount of citrulline generated was quantified by a colorimetric assay. PAD isotypes present in ECV304 were determined by PCR. ECV304 citrullinated proteins/peptides were immunoprecipitated by autoantibodies present in RA sera, and characterized by mass spectrometry. The ECV304-based ELISA contained a citrullinated ECV304 cell extract and myelin basic protein (MBP, an arginine-rich potential citrullinated -epitope carrier). The performance of this assay was tested in sera from 1) 74 patients with a clinical diagnosis of RA (55 CCP positive, 50 rheumatoid factor [RF] positive; 8 CCP and RF negative), 2) 51 patients with non-RA rheumatic diseases (non-RA controls), and 3) 25 healthy controls.

Results: Among 7 human cell lines tested, ECV304 was the only one that abundantly citrullinated self-proteins and exogenous MBP. ECV304 expressed PAD2 and PAD3 iso-enzymes, and the ECV304 citrullinated proteins/peptides were detected by autoantibodies present in RA sera. Proteomic analysis confirmed the presence of known citrullinated RA antigens (i.e., calreticulin, profiling 1 and vinculin), as well as novel targets such as: 14-3-3 protein beta/alpha, 14-3-3 protein zeta/delta, mitochondrial peroxiredoxin-5, and transkelotase in the ECV304 extracts. The net binding to ECV304 citrullinated proteins (compared to non-citrullinated proteins) was the ELISA readout, and the cut-off of the test was defined to optimize specificity. The sensitivity, specificity, positive and negative predictive values of the ECV304-based ELISA were 39%, 98%, 97% and 63%, respectively.

Conclusion: The human cell line ECV304 possesses all the molecular machinery to citrullinate self-proteins that are recognized by ACPA-positive RA sera. Due to its high specificity, and low cost, the ECV304-based ELISA could represent an alternative to ACPA tests for the diagnosis of RA in resource-limited settings.


Disclosure: N. R. de Franca Shimabukuro, None; M. Lora, None; M. Useche, None; Z. Zhou, None; J. Rauch, None; L. E. Coelho Andrade, None; H. Menard, None; I. Colmegna, None.

To cite this abstract in AMA style:

de Franca Shimabukuro NR, Lora M, Useche M, Zhou Z, Rauch J, Coelho Andrade LE, Menard H, Colmegna I. ECV304 Cells Self-Citrullinate Proteins Targeted By Anti-Citrullinated Protein/Peptide Autoantibodies from Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/ecv304-cells-self-citrullinate-proteins-targeted-by-anti-citrullinated-protein-peptide-autoantibodies-from-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ecv304-cells-self-citrullinate-proteins-targeted-by-anti-citrullinated-protein-peptide-autoantibodies-from-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology